NASDAQ$ANNX
Annexon Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Annexon reported third quarter 2024 financial results and highlighted portfolio progress.
Annexon's third quarter 2024 results highlighted the company's progress in its clinical programs, including ANX005, ANX007, and ANX1502. The company's cash, cash equivalents, and short-term investments totaled $340.1 million as of September 30, 2024, which is expected to fund operations into the second half of 2026.
- Topline RWE data for ANX005 in GBS is expected by year-end 2024, with a BLA submission targeted for the first half of 2025.
- Enrollment is ongoing in the Phase 3 ARCHER II trial for ANX007 in GA, with topline data expected in the second half of 2026.
- A proof-of-concept study with the oral C1s inhibitor ANX1502 transitioned to an enhanced tablet formulation, with data in CAD expected in the first quarter of 2025.
- The company's balance sheet is robust, with cash, cash equivalents, and short-term investments of approximately $340 million as of September 30, 2024, anticipated to provide runway into the second half of 2026.
Headline financials
Revenue & EPS history
Annexon · Revenue · Quarterly
$0
Forward guidance
Annexon anticipates several key milestones for its flagship programs.
Tailwinds
- ANX005 in GBS: Initial topline data from RWE comparability protocol with IGOS expected by year-end 2024 to support a planned BLA submission in the first half of 2025
- ANX007 in GA: Phase 3 ARCHER II trial topline data expected in the second half of 2026.
- ANX1502 in CAD: Initial data from POC trial evaluating the pharmacodynamics of an oral tablet formulation in CAD expected in the first quarter of 2025
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2024
+3.0%
Avg return
Earnings day
+2.5%
Avg return
5 days after
+1.8%
Avg return
30 days after
64%
14 / 22 earnings
Positive
+23.1%
Q1 2022
Best reaction
-8.1%
Q4 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -6.9% | -4.6% | -7.4% | |
| Q3 2025 | -0.7% | -9.1% | +69.1% | |
| Q1 2025 | +9.4% | +8.8% | +37.6% | |
| Q4 2024 | +3.3% | +15.5% | -23.4% | |
| Q3 2024 | -6.6% | -16.6% | -32.2% | |
| Q2 2024 | +3.8% | +11.3% | +12.8% | |
| Q1 2024 | +1.5% | -8.8% | +27.2% | |
| Q4 2023 | +17.6% | +8.0% | -30.9% | |
| Q3 2023 | +16.7% | +22.4% | +23.8% | |
| Q2 2023 | -1.2% | -2.1% | -26.6% | |
| Q1 2023 | +4.2% | +3.7% | -40.7% | |
| Q4 2022 | +3.8% | -8.0% | -15.0% | |
| Q3 2022 | -0.4% | +16.6% | +15.8% | |
| Q2 2022 | +3.1% | +17.2% | +10.2% | |
| Q1 2022 | +23.1% | +25.0% | +51.2% | |
| Q4 2021 | -5.1% | -11.0% | -43.8% | |
| Q3 2021 | +1.3% | +0.2% | -3.4% | |
| Q2 2021 | -4.6% | -13.7% | +11.6% | |
| Q1 2021 | +1.1% | +9.3% | +12.6% | |
| Q4 2020 | -8.1% | -17.4% | -29.5% | |
| Q3 2020 | +3.5% | +9.1% | +13.0% | |
| Q2 2020 | +6.6% | -1.2% | +8.9% | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro